相关实验视频

Updated: Jul 2, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

一个电子心理健康干预措施,以减少肥胖个体的抑郁症状:随机,受控,双臂,确认LightMood试验的研究协议

Dilara Kocol^1,2, Sheila Geiger^3,4, Adam Schweda^3,4

¹Clinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Dilara.kocol@lvr.de.

|February 28, 2024

概括

这项研究测试了LightMood对患有抑郁症的肥胖患者的数字干预. 与标准护理相比,LightMood在减少抑郁症症状方面表现有前途,提供低门电子心理健康解决方案.

科学领域:

精神病学和数字健康
肥胖医学肥胖医学
临床心理学临床心理学

背景情况:

肥胖经常与心理困扰,特别是抑郁症有关.
像医疗应用程序这样的数字干预措施为面临医疗保健障碍的人提供了可访问的支持.
"LightMood干预"是一款专为患有抑郁症的肥胖患者而设计的数字工具.

研究的目的:

评估LightMood干预措施在减轻肥胖患者抑郁症症状方面的有效性.
为了比较LightMood与通常治疗 (TAU) 的有效性.
探索电子心理健康干预措施对这一群体的可行性,有效性和接受度.

主要方法:

一项前性随机对照试验,涉及128名患有肥胖和抑郁症 (PHQ ≥10) 的参与者.
参与者被随机分配到LightMood干预或TAU.
评估包括基线,治疗后和1个月和3个月的随访,测量抑郁症,自我效能,生活质量,正念,饮食障碍症状和BMI.

主要成果:

该研究预计,LightMood干预措施在减少抑郁症症状方面将优于TAU.
在所有测量时间点中,预计抑郁症症状的预期积极发展.
二次结果包括自我效能,生活质量和正念的改善.

结论:

LightMood是一个基于证据的,高效的,可访问的在线干预措施,用于减少肥胖患者的抑郁症.
在线干预是传统面对面治疗的可行替代方案.
该研究旨在提供关于电子心理健康解决方案对肥胖和抑郁症的有用性的关键见解.

关键词:

这是CBT CBT.抑郁症抑郁症抑郁症正念是一种正念.肥胖问题肥胖问题在线干预在线干预随机对照试验是随机对照试验.电子健康电子健康

更多相关视频

Control of Eating Behavior Using a Novel Feedback System

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Visualization of Intensity Levels to Reduce the Gap Between Self-Reported and Directly Measured Physical Activity

Visualization of Intensity Levels to Reduce the Gap Between Self-Reported and Directly Measured Physical Activity

Published on: March 7, 2019

相关概念视频

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...